These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11454872)

  • 1. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.
    Maeda K; Yoshimura K; Shibayama S; Habashita H; Tada H; Sagawa K; Miyakawa T; Aoki M; Fukushima D; Mitsuya H
    J Biol Chem; 2001 Sep; 276(37):35194-200. PubMed ID: 11454872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
    Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
    J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.
    Habashita H; Kokubo M; Hamano S; Hamanaka N; Toda M; Shibayama S; Tada H; Sagawa K; Fukushima D; Maeda K; Mitsuya H
    J Med Chem; 2006 Jul; 49(14):4140-52. PubMed ID: 16821774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV co-receptors as targets for antiviral therapy.
    Schols D
    Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
    Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
    J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
    Baba M; Takashima K; Miyake H; Kanzaki N; Teshima K; Wang X; Shiraishi M; Iizawa Y
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4584-91. PubMed ID: 16251299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The B-oligomer of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains.
    Alfano M; Schmidtmayerova H; Amella CA; Pushkarsky T; Bukrinsky M
    J Exp Med; 1999 Sep; 190(5):597-605. PubMed ID: 10477545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages.
    Aquaro S; Menten P; Struyf S; Proost P; Van Damme J; De Clercq E; Schols D
    J Virol; 2001 May; 75(9):4402-6. PubMed ID: 11287590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs.
    Nakata H; Steinberg SM; Koh Y; Maeda K; Takaoka Y; Tamamura H; Fujii N; Mitsuya H
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2111-9. PubMed ID: 18378711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha.
    Maeda Y; Foda M; Matsushita S; Harada S
    J Virol; 2000 Feb; 74(4):1787-93. PubMed ID: 10644351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.
    Baba M; Nishimura O; Kanzaki N; Okamoto M; Sawada H; Iizawa Y; Shiraishi M; Aramaki Y; Okonogi K; Ogawa Y; Meguro K; Fujino M
    Proc Natl Acad Sci U S A; 1999 May; 96(10):5698-703. PubMed ID: 10318947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s.
    Nakata H; Maeda K; Das D; Chang SB; Matsuda K; Rao KV; Harada S; Yoshimura K; Ghosh AK; Mitsuya H
    Sci Rep; 2019 Mar; 9(1):4828. PubMed ID: 30886166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited expression of R5-tropic HIV-1 in CCR5-positive type 1-polarized T cells explained by their ability to produce RANTES, MIP-1alpha, and MIP-1beta.
    Annunziato F; Galli G; Nappi F; Cosmi L; Manetti R; Maggi E; Ensoli B; Romagnani S
    Blood; 2000 Feb; 95(4):1167-74. PubMed ID: 10666186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist.
    Blanpain C; Migeotte I; Lee B; Vakili J; Doranz BJ; Govaerts C; Vassart G; Doms RW; Parmentier M
    Blood; 1999 Sep; 94(6):1899-905. PubMed ID: 10477718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
    De Clercq E; Schols D
    Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
    Takashima K; Miyake H; Kanzaki N; Tagawa Y; Wang X; Sugihara Y; Iizawa Y; Baba M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3474-82. PubMed ID: 16048963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel reporter T-cell line highly susceptible to both CCR5- and CXCR4-using human immunodeficiency virus type 1 and its application to drug susceptibility tests.
    Miyake H; Iizawa Y; Baba M
    J Clin Microbiol; 2003 Jun; 41(6):2515-21. PubMed ID: 12791875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase of R5 HIV-1 infection and CCR5 expression in T cells treated with high concentrations of CXCR4 antagonists and SDF-1.
    Gotoh K; Yoshimori M; Kanbara K; Tamamura H; Kanamoto T; Mochizuki K; Fujii N; Nakashima H
    J Infect Chemother; 2001 Mar; 7(1):28-36. PubMed ID: 11406754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
    Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
    J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diverging binding capacities of natural LD78beta isoforms of macrophage inflammatory protein-1alpha to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophils.
    Struyf S; Menten P; Lenaerts JP; Put W; D'Haese A; De Clercq E; Schols D; Proost P; Van Damme J
    Eur J Immunol; 2001 Jul; 31(7):2170-8. PubMed ID: 11449371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.